Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,38
KB-1,24
PKN109,35106,2-0,05
Msft2,55
IBM-0,97
DCX70,9570,980,17
PFE2,03
16.12.2017 2:10:00
Indexy online
AD Index online
select
AD Index online
 

  • 15.12.2017
Karyopharm Therap (NASDAQ Cons)
Závěr k 15.12.2017 Změna (%) Změna (USD) Objem obchodů (ks)
9,24 -0,11 -0,01 407 881
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 17.12.2017
Popis společnosti
Obecné informace
Název společnostiKaryopharm Therapeutics Inc
TickerKPTI
Kmenové akcie:Ordinary Shares
RICKPTI.O
ISINUS48576U1060
Prioritní akcieConv. Pref. Shrs Series A
Prioritní akcieConv. Pref. Shrs Series B
Prioritní akcieConv. Pref. Shrs Series A-2
Prioritní akcieConv. Pref. Shrs Series A-3
Prioritní akcieConv. Pref. Shrs Series A-4
Prioritní akcieConv. Pref. Shrs Series B-1
Poslední známé roční výsledky31.12.2016
Poslední známé čtvrtletní výsledky30.9.2017
Počet zaměstnanců k 1.3.2017 108
Akcie v oběhu k 30.10.2017 47 180 775
Počet akcionářů k 31.12.2016 13
MěnaUSD
Kontaktní informace
Ulice85 Wells Ave
MěstoNEWTON CENTER
PSČ02459-3298
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon16 176 580 600
Fax13026555049

Business Summary: Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. The Company's lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. It is also engaged in the clinical development of selinexor in various solid tumor indications. Oral selinexor is being evaluated in multiple later-phase clinical trials in patients with relapsed and/or refractory hematological and solid tumor malignancies. Its lead drug candidate, oral selinexor (KPT-330), as well as verdinexor (KPT-335), KPT-8602 and KPT-9274 are in clinical development.
Financial Summary: BRIEF: For the nine months ended 30 September 2017, Karyopharm Therapeutics Inc revenues decreased 34% to $71K. Net loss increased 9% to $89.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and Development increase of 9% to $72.4M (expense), General and Administrative increase of 8% to $18.7M (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
NAICSMedicinal and Botanical Manufacturing
SICPharmaceutical Preparations
SICCommercial Physical Research
SICMedicinals And Botanicals



  • Poslední aktualizace: 17.12.2017
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Co-Founder, Chief Scientific Officer, DirectorSharon Shacham465.12.2013
Co-Founder, Chief Executive Officer and DirectorMichael Kauffman53
Chief Financial Officer, Executive Vice President, Treasurer, Principal Financial Officer, Principal Accounting OfficerMichael Falvey5811.9.201711.9.2017
Senior Vice President, General Counsel, SecretaryChristopher Primiano36
Vice President - Finance, Assistant TreasurerMichael Todisco5211.9.2017
Chief Development Operations OfficerRan Frenkel487.6.2015